SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-158374
Filing Date
2024-06-10
Accepted
2024-06-10 16:31:31
Documents
14
Period of Report
2024-06-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d764437d8k.htm   iXBRL 8-K 25362
2 EX-3.1 d764437dex31.htm EX-3.1 6763
  Complete submission text file 0001193125-24-158374.txt   157236

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20240607.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240607_lab.xml EX-101.LAB 17981
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240607_pre.xml EX-101.PRE 11277
18 EXTRACTED XBRL INSTANCE DOCUMENT d764437d8k_htm.xml XML 3784
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 241033201
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)